A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer

Ikeda, Takaya; Fukuda, Minoru; Nakamura, Yoichi; Kinoshita, Akitoshi; Senju, Hiroaki; Nakano, Hirofumi; Kitazaki, Takeshi; Ogawara, Daiki; Taniguchi, Hirokazu; Motoshima, Kohei; Yamaguchi, Hiroyuki; Nakatomi, Katsumi; Shimada, Midori; Nagashima, Seiji; Tsukamoto, Kazuhiro; Kohno, Shigeru

doi:10.1007/s00280-014-2527-4

Cited by 3 publications

(1 citation statement)

References 27 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, this regimen appeared promising in some Japanese trials. 30–33 However, efficacy of AMR is dependent on the race. Our previous analysis revealed that second-line AMR therapy was highly effective in the Japanese population compared with Euro-American populations.…”

Section: Discussionmentioning

confidence: 99%

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background: Our goal was to organize the data from randomized controlled trials that evaluated first-line chemotherapy for chemo-naïve extensive disease small-cell lung cancer (ED-SCLC). Methods: The protocol following PRISMA methodology was submitted as PROSPERO 154049. We included individually randomized trials comparing two or more chemotherapy regimens as the first-line treatment for chemo-naïve ED-SCLC regardless of the age, sex, performance status, co-morbidities, and organ functions written in the English language since 2000. Molecular targeted agents and immune checkpoint inhibitors were considered chemotherapy along with cytotoxic medications. We pooled the logarithm of hazard ratio (HR) and its standard error using the frequentist weighted least squares approach random-model network meta-analysis. Results: A total of 46 eligible trials that involved 11,987 patients were included. The primary endpoint, HR of overall survival (OS, HRos) of the selected comparisons was as follows: carboplatin+amrubicin (HRos 0.56, 95% confidence interval (CI) 0.33–0.96), carboplatin+etoposide+atezolizumab (HRos 0.70, 95% CI 0.53–0.92), and carboplatin+irinotecan (HRos 0.73, 95% CI 0.58–0.91) were compared with carboplatin+etoposide. The carboplatin+etoposide+atezolizumab regimen was compared with carboplatin+irinotecan (HRos 0.97, 95% CI 0.68–1.37) and cisplatin+irinotecan regimen (HRos 0.87, 95% CI 0.58–1.31). “Selective carboplatin or cisplatin (CBDCA/CDDP)”+etoposide+durvalumab was compared with CBDCA/CDDP+etoposide (HRos 0.73, 95% CI 0.59–0.91). Platinum+etoposide+durvalumab was compared with platinum+irinotecan (HRos 0.88, 95% CI 0.67–1.15). Cumulative meta-analysis suggested that platinum+irinotecan was associated with better OS than platinum+etoposide as of 2010 through 40 out of 46 trials in our review that used platinum+etoposide as a reference regimen. Conclusion: Patients treated with carboplatin+amrubicin, carboplatin+etoposide+atezolizumab, CBDCA/CDDP+etoposide+durvalumab, and platinum+irinotecan showed better HRos than those treated with platinum+etoposide, one of the standard regimens.

show abstract

Section: Discussionmentioning

confidence: 99%

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901

et al. 2017

View full text Add to dashboard Cite

Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional study

Miura

Saito

Atsumi

et al. 2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

Objective: Amrubicin, which is used as a chemotherapeutic agent for lung cancer, can induce interstitial lung disease. There is insufficient evidence on the incidence of amrubicin-associated interstitial lung disease under practical use settings. We therefore investigated the occurrence of interstitial lung disease in the patients with lung cancer who received amrubicin in our institution. Methods: We reviewed the data of all patients with lung cancer who

show abstract

A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer

Abstract: Background: Amrubicin is active in the treatment of extensive-disease small

Cited by 3 publications

References 27 publications

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis

Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901

Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional study

Contact Info

Product

Resources

About